Research & Development Jobs in Life Sciences’ Post

I have successfully completed the Drug Discovery course and got the certification from the esteemed University of California San Diego! This milestone highlights your dedication to mastering the intricate processes involved in identifying and developing novel therapeutic compounds. The program has likely equipped you with a comprehensive grasp of the various stages, from target identification and lead compound screening to optimization, preclinical testing, and clinical trials. Moreover, I have likely gained valuable insights into cutting-edge techniques like high-throughput screening, computational modelling, and structure-based drug design, widely employed in modern drug discovery endeavours. #LifeSciences #MedicinalChemistry #Pharmacology #DrugDiscovery #Certification #UCSD #PharmaResearch #TherapeuticDevelopment #pharmaceutical #biotechnology #academic #CareerOpportunities #professional #LifeSciences #MedicinalChemistry #Pharmacology

I recently completed the course "Drug Development: Combating Pain" on OpenLearn. This course gave me a comprehensive overview of the drug development process, from identifying a suitable candidate drug molecule to the development of a commercial drug product available in the clinic for pain relief or as an anti-inflammatory. I learned about the different stages of drug development, including target identification, lead discovery, preclinical testing, clinical trials, and regulatory approval. I also learned about the challenges and complexities of drug development, such as the high cost of research and development, the long time it takes to bring a new drug to market, and the risk of failure. Despite the challenges, I am excited about the potential of drug development to improve the lives of people with pain. I believe that this course has given me a valuable foundation for a career in drug discovery or development. If you are interested in learning more about drug development, I encourage you to take this course. It is a valuable resource for anyone who wants to understand the complex process of bringing new drugs to market. #drugdevelopment #painmanagement #newdrugs #healthcare #science

💊 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗹𝗼𝗻𝗴 𝘄𝗶𝘁𝗵 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗮𝗿𝗲 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗰𝗼𝗺𝗽𝗼𝗻𝗲𝗻𝘁𝘀 𝗼𝗳 𝗮𝗻 𝗼𝗽𝘁𝗶𝗺𝗮𝗹 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆. Modeling and simulations play a pivotal role in drug development by offering cost-effective and time-efficient alternatives to traditional clinical trial approaches. By providing valuable insights into clinical pharmacology and pharmacokinetics, modeling and simulations significantly contribute to accelerating the drug development process, reducing expenses, and ultimately fostering the creation of safer and more effective pharmaceuticals. ➡https://lnkd.in/diugenU #drugdevelopment #modelingandsimulation #pharmacokinetics

Deepen Your Understanding of the Early Drug Discovery Process A deeper understanding of the drug discovery process is essential to ensure drugs successfully advance through the clinic and reach registration. This classic article from 2011, published in the British Journal of Pharmacology provides a concise overview of the key steps involved in drug discovery space, from the initial identification of promising molecules (hit discovery) to their refinement into optimized drug candidates (lead optimization). Understanding the complexities and intricacies of each stage can foster better #collaboration and #communication between clinical development professionals and their earlier-stage counterparts in the drug discovery process. Key Takeaways: ✅ Hit discovery: Researchers utilize various techniques like high-throughput screening and computational modeling to identify molecules that interact with the target of interest. ✅ Assay development: Once a "hit" is identified, assays are developed to measure its potency and selectivity, determining its suitability for further development. ✅ Defining a hit series: Medicinal chemistry is employed to optimize the initial hit compound, creating a series of related molecules with enhanced properties. ✅ Hit-to-lead optimization: This stage focuses on further refining the hit compound to improve its potency, selectivity, and other essential characteristics. ✅ Lead optimization: The final preclinical stage involves meticulously optimizing the lead compound into a drug candidate suitable for clinical trials. Expand your knowledge and gain a holistic perspective on the drug discovery journey. Link to the article: https://lnkd.in/gjU9JDem ⭐ ⭐ ⭐ Send a note if you want to explore how I can support your drug development needs. Connect or follow to stay informed of drug development trends. ⭐ ⭐ ⭐ #drugdiscovery #clinicaldevelopment #pharmaceuticalresearch

After a brief yet impactful tenure as the Senior Director of CMC Program Management, Industrial Operations, and Product Supply (IOPS) at Regeneron, I am thrilled to announce my new venture as a Principal Consultant at WA Consultation LLC. At WA Consultation LLC, I leverage extensive experience in pharmaceuticals, biopharmaceuticals, and combinational products/devices to deliver actionable strategies and drive measurable results across diverse therapeutic areas including biologics, cell and gene therapies (CGT), oligonucleotides (Oligos), mRNA, small molecules, peptides, blood plasma products, and antibody-drug conjugates (ADCs) and more. My focus areas include: ✅ End-to-End CMC Development and Industrialization: Streamlining program management, production processes, analytical development, formulation, devices, supply chain, operations, technology evaluation and implementation, business partnerships, and successful CMC regulatory filings. ✅ Lifecycle Management and Global Markets Optimization: From preclinical stages through development to successful commercialization, ensuring smooth transitions and optimal resource allocation across various global markets. ✅ Accelerating Business Growth: Supporting business development, new product launches, technology evaluation, strategic implementations, and partnerships with CDMOs and CROs to maximize market penetration and business expansion. ✅ Enhancing Operational Efficiency: Implementing efficient workflows, reporting structures, and functional reorganizations to boost team productivity and project execution. ✅ Elevating Clinical Operations: Enhancing site management, evaluating solutions, and optimizing bioanalytical labs to accelerate clinical trials and ensure high-quality data delivery. ✅ Strengthening Intellectual Property and Data Management: Providing expert guidance on patent infringement, technology patentability, and data evaluation to protect organizational assets and enhance competitive advantage. I am passionate about championing initiatives that enhance business value through digital transformation and streamlined workflows, ultimately driving sustainable growth and competitive advantage for your organization. If your organization is seeking expert guidance in product and technology development or is looking to accelerate business growth and achieve transformative results, let's connect! I look forward to partnering with you and contributing to your organization's success. Thank you to all my colleagues, mentors, and partners for your unwavering support. I am excited about this next phase of my career. #Consulting #ProgramManagement #Biotech #Pharma #CMC #BusinessDevelopment #DigitalTransformation #Biopharma #HealthcareConsulting #Innovation #ClinicalOperations #Bioanalytical #StrategicPartnerships #RegulatoryAffairs #GlobalMarkets #VCpharma #venturecapital

Drug Discovery Outsourcing: A Comprehensive Snapshot 🌐🔬 Market Growth: The global drug discovery outsourcing arena was valued at a staggering USD 3.5 billion in 2022, forecasted to soar with a 7.3% CAGR from 2023-2030. Post-COVID, industry leaders are steering significant strategic shifts to stay afloat in the dynamic landscape. Outsourcing is the new norm, buoyed by past paradigm shifts in the pharma sector. Therapeutics Breakdown: Respiratory systems took the lion's share in 2022, holding 14% of global revenue. Spurring its growth is the high prevalence of respiratory ailments and the advent of innovative drug delivery techniques, like nasal sprays. Yet, oncology and anti-infectives are the ones to watch, expected to record remarkable CAGRs soon. Small Molecules Lead the Charge 🧪: Their efficacy and versatility have crowned small molecules the champions of the pharmaceutical portfolio. Preferred for their oral administration capabilities, cost-effectiveness, and synergy with intracellular targets, they dominated the market in 2022 with a whopping 77.7% share. Services & End-Users 📊: - Chemistry Services: The top choice, thanks to surging small molecule projects.  - Biology Services: Anticipated to grow at 7.5% CAGR from 2023-2030, driven by technical expertise demand and industry bigwigs like Eurofins and Syngene. - Pharma & Biotech Companies: These behemoths captured 79.8% of 2022's revenue, propelled by a burgeoning R&D pipeline and the rising tide of global diseases. Regional Rundown 🌍: North America reigned supreme in 2022, bagging over 35.5% of the global pie. But Asia, with its skilled workforce, cost benefits, and regulatory perks, is fast emerging as the new mecca for drug discovery outsourcing. As we journey through this evolving domain, collaborations, innovations, and patient-first approaches light our path. #DrugDiscoveryOutsourcing #MarketInsights #PharmaTrends Seek a deeper dive? Explore the full report. 📊🔍 Link in the post

As the industry acclimatizes to macroeconomic uncertainties, analysts predict a number of factors will drive growth in the life sciences M&A arena this year. From a looming $100 billion patent cliff to an unprecedented $1.4 trillion in firepower on the table, here’s how M&A is unfolding in 2023. #lifesciences #biopharma #biotech #pharmaceuticals #pharmaceuticalindustry #mergersandacquisitions

🚀💊 𝐓𝐫𝐞𝐧𝐝𝐬 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐚𝐧𝐝 𝐁𝐞𝐲𝐨𝐧𝐝! The pharmaceutical landscape is evolving rapidly, with a myriad of challenges and opportunities reshaping the industry. Let's dive into some key insights and trends that are driving this transformation: 🔍 𝐒𝐦𝐚𝐥𝐥 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐃𝐫𝐮𝐠𝐬: Despite challenges, small molecule drugs continue to dominate the market. Their precise control over structure and properties make them vital for treating various diseases. 🔬𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: The rise of biologics has revolutionized treatment landscapes, offering targeted therapies for conditions like oncology and autoimmune disorders. Expect continued growth and innovation in this space. 💡𝐎𝐮𝐭𝐬𝐨𝐮𝐫𝐜𝐢𝐧𝐠 & 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: Outsourcing in drug development accelerates time-to-market, while personalized medicine driven by genomics and AI enhances treatment precision and efficacy. As we navigate these dynamic trends, collaboration and innovation will be pivotal in driving positive change and improving global healthcare outcomes. Excited to be part of this transformative journey at Pharmaron! 💼💡 #PharmaceuticalIndustry #Innovation #HealthcareTransformation

Exciting #GenAI breakthroughs are advancing drug discovery in #biopharmaceutical research. Insights from EY-Parthenon show that GenAI can speed up the early stages of drug development, from finding targets to creating new molecules - potentially cutting costs by up to 67%. Successfully integrating GenAI requires firms to assess their technological options, decide whether to build, buy, or partner for GenAI capabilities, and align these initiatives with their organizational culture and ethical guidelines. This strategic approach aims to harness GenAI's promise of quicker, cost-effective drug development and bringing new treatments to market more efficiently. https://lnkd.in/eNPP3zdE #Pharma

U.S. Clinical Trial Imaging Sector Set to Double by 2033 The U.S. clinical trial imaging market is projected to double in value by 2033, reaching $875.93 million with a CAGR of 7.9%. This growth is driven by increased investments in pharmaceuticals and biotechnology, as well as a rise in R&D activities. The market is segmented into various services, with project and data management services leading at 28.17%, and CT scans as the dominant modality at 29.19%. Oncology is the largest application segment, holding a 26.17% market share. The market is witnessing a shift towards decentralized trials, the integration of AI, and the adoption of advanced imaging technologies. Strategic partnerships and innovations, such as GE HealthCare’s collaboration with Mayo Clinic, are further fueling market growth. Companies like ProScan Imaging, IXICO plc, and Biomedical Systems Corp are leading advancements in the field. AI and a focus on oncology applications offer potential advantages. The dynamic nature of the pharmaceutical and biotechnology industries necessitates the integration of new technologies and partnerships. Staying updated on these trends will be crucial for stakeholders to seize opportunities in this promising market. For more details please click the link! https://lnkd.in/dcDB3v_n #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical